Eurbio-Alport (RaDiCo Cohort) (RaDiCo Eurbio-Alport)

Official title

Study of the Natural History of Alport Syndrome by Establishment of an International Database

Overview

Alport syndrome is a rare, inherited condition characterized by a combination of glomerular nephropathy progressing to kidney failure, deafness, and eye involvement. This disease is associated with mutations in the genes encoding one of the three IV collagen chains expressed in the glomerular basement membrane. Significant progress has been made in understanding the molecular mechanisms responsible for the disease, but relatively little in understanding the progression of renal failure and in the area of therapeutics. We have shown in a retrospective European study that blockers of the renin angiotensin system may slow disease progression, but no controlled studies have been performed. Finally, innovative therapies (anti-micro-RNA, stem cells) have recently shown their effectiveness in animal models of the disease, and industrials are planning to quickly carry out phase 1 trials to test molecules. Carrying out therapeutic trials in humans will require full knowledge of the natural history of the disease (isolated hematuria, microalbuminuria, macroalbuminuria, renal failure and its progression) and gathering a sufficient number of patients, especially in the early stages. These trials and the indications for treatments would be greatly facilitated by the discovery of biomarkers that make it possible to predict the progression to renal failure earlier than the onset of proteinuria. The study aims to: * Establish a European database on Alport syndrome to assess the natural history of the disease. * To investigate the impact of the disease on the educational and professional life of patients and their families, and on the adherence and tolerance to renin-angiotensin system blockers prescribed to proteinuric patients. * Investigate access to molecular diagnostics and genetic counseling, as well as identify biomarkers that can predict progression of kidney disease. This project will be carried out at a French level with the support and participation of the very active renal rare disease sector, in collaboration with various countries wishing to participate.

Primary outcome measures

• Renal function: eGFR, age at ESRD, requirement of Renal Replacement Therapy (RRT) and type of RRT [Time frame: Through study completion, at 1 year, 2 year, 3 year]
• Urine bio-analysis results: Presence or not and quantification of hematuria, microalbuminuria and proteinuria [Time frame: Through study completion, at 1 year, 2 year, 3 year]
• Presence or not of hypertension [Time frame: Through study completion, at 1 year, 2 year, 3 year]
• Level of Hearing loss [Time frame: Through study completion, at 1 year, 2 year, 3 year]
• Ocular symptoms (presence or not of lenticonus, cataract, retina and cornea impairment) [Time frame: Through study completion, at 1 year, 2 year, 3 year]

Secondary outcome measures (3)

• Adverse events for the long-term safety of RAAS blockers treatment [Time frame: Through study completion, at 1 year, 2 year, 3 year]
• Quality of life questionnaires [Time frame: Through study completion, at 1 year, 2 year, 3 year]
• Compliance [Time frame: Throughout the follow-up]

Eligibility criteria

Inclusion criteria

• Diagnosis of AS based on electron microscopic examination of the renal biopsy and/or molecular studies and/or abnormal expression of type IV collagen chains on skin and/or glomerular basement membranes.
• Signed informed consent

Exclusion criteria

\- No exclusion criteria

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model

Cohort

Study locations

France · 1 center

• RaDiCo Eurbio-Alport — Paris

Identifiers

NCT: NCT05927467 · C15-82

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗